Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Ajanta-Pharma-Limited"

6 News Found

Ajanta Pharma posts Q1 FY25 consolidated PAT at Rs. 245.77 Cr
News | August 01, 2024

Ajanta Pharma posts Q1 FY25 consolidated PAT at Rs. 245.77 Cr

Ajanta Pharma has reported total income of Rs. 1,171.39 crores during the period ended June 30, 2024

Ajanta Pharma posts Q4 FY24 consolidated PAT at Rs. 202.72 Cr
News | May 04, 2024

Ajanta Pharma posts Q4 FY24 consolidated PAT at Rs. 202.72 Cr

The company has reported total income of Rs. 1,089.58 crores during the period ended March 31, 2024

Ajanta Pharma posts Q2 FY24 consolidated PAT at Rs. 195.30 Cr
News | November 01, 2023

Ajanta Pharma posts Q2 FY24 consolidated PAT at Rs. 195.30 Cr

Ajanta Pharma has reported total income of Rs. 1049.77 crores during the period ended September 30, 2023

Ajanta Pharma receives USFDA for Topiramate Extended Release Capsules
Drug Approval | August 31, 2023

Ajanta Pharma receives USFDA for Topiramate Extended Release Capsules

Topiramate is the generic version of Supernus Pharmaceuticals’ Trokendi XR

Ajanta Pharma's Q1 FY24 consolidated PAT up at Rs. 208.12 Cr
News | July 28, 2023

Ajanta Pharma's Q1 FY24 consolidated PAT up at Rs. 208.12 Cr

The company has reported total income of Rs. 1052.79 crores during the period ended June 30, 2023

Ajanta pharma posts Q4FY23 consolidated PAT at Rs. 122.25 Cr
News | May 06, 2023

Ajanta pharma posts Q4FY23 consolidated PAT at Rs. 122.25 Cr

The company has reported total income of Rs. 918.67 crores during the period ended March 31, 2023

Latest Stories

Vimta Labs posts Q4 FY25 PAT at Rs. 18.31 Cr

Sigachi Industries signs MoU with Respilon Group

USFDA inspects Marksans’s subsidiary Time-Cap Laboratories' manufacturing facility

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging